Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Long-Term Deferred Tax (2025)

Historic Long-Term Deferred Tax for Krystal Biotech (KRYS) over the last 1 years, with Q4 2025 value amounting to $22.8 million.

  • Krystal Biotech's Long-Term Deferred Tax changed N/A to $22.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $22.8 million, marking a year-over-year change of. This contributed to the annual value of $22.8 million for FY2025, which is N/A changed from last year.
  • Latest data reveals that Krystal Biotech reported Long-Term Deferred Tax of $22.8 million as of Q4 2025.
  • Krystal Biotech's 5-year Long-Term Deferred Tax high stood at $24.7 million for Q3 2025, and its period low was $22.8 million during Q4 2025.